Roles and inhibitors of FAK in cancer: current advances and future directions

HH Hu, SQ Wang, HL Shang, HF Lv… - Frontiers in …, 2024 - frontiersin.org
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that exhibits high expression
in various tumors and is associated with a poor prognosis. FAK activation promotes tumor …

[HTML][HTML] High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma

N Arang, S Lubrano, M Ceribelli, DC Rigiracciolo… - Cell Reports …, 2023 - cell.com
Uveal melanoma (UM) is the most prevalent cancer of the eye in adults, driven by activating
mutation of GNAQ/GNA11; however, there are limited therapies against UM and metastatic …

Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma

A Haugh, AI Daud - American Journal of Clinical Dermatology, 2024 - Springer
There have been many recent advances in melanoma therapy. While 50% of melanomas
have a BRAF mutation and are a target for BRAF inhibitors, the remaining 50% are BRAF …

Recent Advances in Molecular and Genetic Research on Uveal Melanoma

A Fuentes-Rodriguez, A Mitchell, SL Guérin… - Cells, 2024 - mdpi.com
Uveal melanoma (UM), a distinct subtype of melanoma, presents unique challenges in its
clinical management due to its complex molecular landscape and tendency for liver …

Uveal Melanoma: Molecular and Genetic Mechanisms of Development and Therapeutic Approaches

MV Zhilnikova, OS Troitskaya, DD Novak… - Molecular Biology, 2024 - Springer
Uveal melanoma (UM) is a neuroectodermal tumor that results from malignant
transformation of melanocytes in the eye uvea, including the iris, the ciliary body, and the …